> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Pediatric Oncology Meeting Planned for 6/21-22
- URL: https://www.fdaweb.com/pediatric-oncology-meeting-planned-for-6-21-22/
- Published: 2017-05-31T12:00:00.000Z
- Updated: 2026-09-14T22:26:35.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138825

*Federal Register* notice: FDA has announced a 6/21-22 Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee meeting. On 6/21, information will be presented to gauge investigator interest in exploring potential pediatric development plans for three products in various stages of development for adult cancer indications. Products under consideration are: (**1**) Apexigen’s APX–005M; (**2**) PharmaMar USA’s PMO1183 (lurbinectedin); and (**3**) Astellas’ ASP2215 (gilteritinib). The subcommittee will consider and discuss issues concerning diseases to be studied, patient populations to be included, and possible study designs. On 6/22, information will be presented to gauge investigator interest in exploring potential pediatric development plans for two products in various stages of development for adult cancer indications. Products under consideration are: (**1**) Dista Products/Eli Lilly’s prexasertib; and (**2**) Eli Lilly’s olaratumab. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-05-30/pdf/2017-11030.pdf?ref=fdaweb.com).